Work

Brain somatic mutations in MTOR reveal translational dysregulations underlying intractable focal epilepsy

Year: 2019
Type: article
Abstract: 10).Interestingly, somatic activating mutations in MTOR with low mutational burden (e.g., mutated allele frequency of ~1% in the affected tissue) have been shown to be sufficient to lead to intractable focal epilepsy (4).The molecular mechanism of how somatic activating mutations in MTOR cause intractable epilepsy, however, has remained elusive.mTOR kinase is a major regulator of translation, which is a fundamental molecular mechanism regulating gene expression (11).Translational dysregulation is thought to underlie the molecular pathogenesis of various human diseases, particularly cancers and neurodevelopmental disorders, as they are associated with the aberrant activation of mTOR (11,12).Accordingly, we hypothesized that translational dysregulation induced by human MTOR mutations may underlie the molecular pathogenesis of intractable epilepsy and other pathologies found in FMCD.However, owing to a lack of disease models of single activating mutations in MTOR, we found understanding of the molecular basis of translational dysregulation directly induced by human MTOR mutations to be lacking: previous studies of mTOR-driven translational control have relied on pharmacological inhibition of mTOR (13, 14).To date, translational profiles in disease models with single MTOR mutations are not available, and questions of how human MTOR mutations lead to disease, which genes are controlled, and how they are regulated remain largely unanswered.In this study using FMCD mouse models, genome-edited cells, and patient brain Brain somatic mutations confer genomic diversity in the human brain and cause neurodevelopmental disorders.Recently, brain somatic activating mutations in MTOR have been identified as a major etiology of intractable epilepsy in patients with cortical malformations.However, the molecular genetic mechanism of how brain somatic mutations in MTOR cause intractable epilepsy has remained elusive.In this study, translational profiling of intractable epilepsy mouse models with brain somatic mutations and genome-edited cells revealed a novel translational dysregulation mechanism and mTOR activation-sensitive targets mediated by human MTOR mutations that lead to intractable epilepsy with cortical malformation.These mTOR targets were found to be regulated by novel mTOR-responsive 5′-UTR motifs, distinct from known mTOR inhibition-sensitive targets regulated by 5′ terminal oligopyrimidine motifs.Novel mTOR target genes were validated in patient brain tissues, and the mTOR downstream effector eIF4E was identified as a new therapeutic target in intractable epilepsy via pharmacological or genetic inhibition.We show that metformin, an FDA-approved eIF4E inhibitor, suppresses intractable epilepsy.Altogether, the present study describes translational dysregulation resulting from brain somatic mutations in MTOR, as well as the pathogenesis and potential therapeutic targets of intractable epilepsy.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2972471297
FWCI: 5.046
Cites: 70
Cited by: 70
Related to: 10
Parts: 1